International Biosimilar Regulations Impede Patient Access to Affordable Medicines

A recent JAMA Health Forum article indicates that varying global regulations for biosimilar drugs across different World Health Organization regions are creating obstacles for patients. These divergent rules limit the widespread availability and use of biosimilars, which are intended to provide more cost-effective alternatives to expensive biologic medications. This regulatory fragmentation ultimately restricts access to crucial, affordable treatments worldwide.